Biological follow-up in amyotrophic lateral sclerosis: Decrease in creatinine levels and increase in ferritin levels predict poor prognosis

European Journal of Neurology

Volumn 22, Issue 10, 2015, Pages 1385-1390

  Patin, F ^a,b   Corcia, P ^a,c   Madji Hounoum, B ^a   Veyrat Durebex, C ^a,b   Respaud, E ^b   Piver, E ^d   Benz de Bretagne, I ^b   Vourc'h, P ^a,b   Andres, C R ^a,b   Blasco, H ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d SERVICE DE DERMATOLOGIE   (France)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Creatinine; Ferritin; Prognostic factors; Survival

Indexed keywords

BIOLOGICAL MARKER; CREATININE; FERRITIN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIOLOGICAL ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; AGED; BLOOD; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; CREATININE; DISEASE PROGRESSION; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84941600495     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12754     Document Type: Article

References (32)

1. Benatar M, Wuu J. Presymptomatic studies in ALS. Neurology 2012; 79: 1732-1739.
2. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009; 10: 310-323.
3. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008; 275: 69-73.
4. Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A. Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol 2014; 11: 1-17.
5. 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology 2014; 82: 1167-1174.
6. Von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P, Neumann B, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One 2012; 7: e44401.
7. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010; 42: 95-103.
8. Su X, Simmons Z, Mitchell R, Kong L, Stephens H, Connor J. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013; 70: 1505-1511.
9. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 37-44.
10. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 2012; 51: 1501-1508.
11. Nadjar Y, Gordon P, Corcia P, Bensimon G, Pieroni L, Meininger V, et al. Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One 2012; 7: e45034.
12. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J-L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004-1009.
13. Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011; 258: 613-617.
14. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills A-M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44: 20-24.
15. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.
16. Veyrat-Durebex C, Corcia P, Mucha A, Benzimra S, Mallet C, Gendrot C, et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed Res Int 2014; 2014: 485723.
17. Ferrières J, Ruidavets JB, Perret B, Dallongeville J, Arveiler D, Bingham A, et al. Prevalence of dyslipidaemias in a representative sample of the French population. Arch Mal Coeur Vaiss 2005; 98: 127-132.
18. Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2009; 73: 1681-1685.
19. Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MHB, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 638-642.
20. Schmitt F, Hussain G, Dupuis L, Loeffler J-P, Henriques A. A plural role for lipids in motor neuron diseases: energy, signaling and structure. Front Cell Neurosci 2014; 8: 25.
21. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler 2012; 13: 110-118.
22. Chen X, Guo X, Huang R, Zheng Z, Chen Y, Shang H. An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis. Neurol Sci 2014; 35: 1591-1597.
23. Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 2011; 258: 238-243.
24. Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 2014; 71: 1134-1142.
25. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008; 3: 348-354.
26. Goodall EF, Haque MS, Morrison PKE. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J Neurol 2008; 255: 1652-1656.
27. Qureshi M, Brown RH Jr, Rogers JT, Cudkowicz ME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J 2008; 2: 51-54.
28. Su XW, Clardy SL, Stephens HE, Simmons Z, Connor JR. Serum ferritin is elevated in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014; 18: 1-6.
29. Hadzhieva M, Kirches E, Mawrin C. Review: Iron metabolism and the role of iron in neurodegenerative disorders. Neuropathol Appl Neurobiol 2014; 40: 240-257.
30. Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, et al. Prevention of motor neuron degeneration by novel iron chelators in SOD transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis 2011; 8: 310-321.
31. Hadzhieva M, Kirches E, Wilisch-Neumann A, Pachow D, Wallesch M, Schoenfeld P, et al. Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience 2013; 230: 94-101.
32. Blasco H, Vourc'h P, Nadjar Y, Ribourtout B, Gordon PH, Guettard Y-O, et al. Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. J Neurol Sci 2011; 303: 124-127.